Key result
Fontan-associated hepatocellular carcinoma lacks robust clinical and outcome data beyond small case series.
Why the study?
Data on hepatocellular carcinoma in patients with Fontan palliation are limited to case reports and small series, leaving clinical characteristics and outcomes poorly understood.
Design
Descriptive study of HCC in Fontan patients
Answers are grounded in this paper and cite their sources.
Limited data on HCC after Fontan warrant surveillance caution; leaves open need for prospective multicenter characterization.
Data regarding hepatocellular carcinoma (HCC) in patients with Fontan palliation are derived predominantly from case reports and small case series. Consequently little is known about the clinical characteristics and outcomes of HCC in Fontan patients. The purpose of this study was to describe
No takes yet. Share an insight, caveat, or question.
Egbe et al. (2018) studied this question. Hepatocellular carcinoma in patients with Fontan palliation currently lacks robust data regarding clinical characteristics and outcomes, relying primarily on small case series.
Synapse has enriched 5 related papers. Consider them for comparative context: